New research has revealed factors associated with an increased risk of COVID-19-related death and hospitalization among patients with cancer.

Topline results were announced from a second phase 3 trial evaluating AD109 (aroxybutynin 2.5mg/atomoxetine 75mg) in patients with OSA.

Medicare fee-for-service beneficiaries had better annual lung cancer screening adherence rates if they underwent a shared ...

Across the recent three months, 5 analysts have shared their insights on 4D Molecular Therapeutics FDMT, expressing a variety ...

On World Cancer Day, a look at how the change is being driven by environmental, occupational and/or genetic risk factors.

Lung cancer in non-smokers is an alarming public health concern, with increasing cases demanding immediate attention beyond ...

Q2 2025 Earnings Call Transcript July 30, 2025 Pulmonx Corporation beats earnings expectations. Reported EPS is $-0.38, ...

I coauthored a paper on a microbe that might incorporate arsenic in its major molecules. It was wrongly retracted. What can ...

PORT TOWNSEND — Jefferson Healthcare has gained occupancy to its new 56,000-square-foot building, most of the paint is dry, ...

The Tamil Nadu government is all set to launch a major healthcare initiative tomorrow in Chennai. The scheme, which focuses ...

Lung function tests play a major role in the diagnosis and treatment of respiratory diseases such as asthma, chronic ...

Lung cancer has long been seen as a smoker’s disease. But a growing crisis is now unfolding quietly in Indian homes. More ...